You are here
Pfizer Response To Initial, Non-Final Office Action by US Patent And Trademark Office
Regarding Company's Application to Reissue Lipitor Calcium Salt Patent
"An initial rejection is not uncommon in reissue application proceedings. Pfizer will now review the communication from the Patent Office and respond as appropriate to address the issues raised by the examiner.
"It is important to note, however, that Lipitor continues to be protected by its basic patent until March 2010, including pediatric exclusivity. Today's decision has no impact on the basic patent.
"The average time for obtaining a reissue patent is about two years from the date the application is filed. Pfizer filed its reissue application on Lipitor's calcium salt patent in January 2007."
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Current Stock Price
|%Change||.||52 Wk. High||.|
|Day High||.||52 Wk. Low||.|
|Day Low||.||Mkt. Cap(Mil)||.|
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.